Uncategorized
Otsuka’s ADHD approval opens up new drug class with $615M opportunity
Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency.